Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma
Recently, progression of disease within 24 months (POD24) has been demonstrated as a strong prognostic indicator in various types of malignant lymphoma. Peripheral T-cell lymphoma (PTCL) has an aggressive course and poor clinical outcomes. In this multicenter retrospective study, 111 consecutively r...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2020-12, Vol.112 (6), p.817-824 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 824 |
|---|---|
| container_issue | 6 |
| container_start_page | 817 |
| container_title | International journal of hematology |
| container_volume | 112 |
| creator | Suzuki, Yasuhiro Yano, Takahiro Suehiro, Youko Iwasaki, Hiromi Hidaka, Michihiro Otsuka, Maki Sunami, Kazutaka Ikeda, Hirokazu Sawamura, Morio Ito, Takuo Iida, Hiroatsu Nagai, Hirokazu |
| description | Recently, progression of disease within 24 months (POD24) has been demonstrated as a strong prognostic indicator in various types of malignant lymphoma. Peripheral T-cell lymphoma (PTCL) has an aggressive course and poor clinical outcomes. In this multicenter retrospective study, 111 consecutively registered patients with newly diagnosed PTCL were analyzed. Of these patients, 72 (64.9%) experienced POD24 (POD24 group), and the other 39 patients (35.1%) were analyzed as the no POD24 group. In the POD24 group, overall survival (OS) was significantly inferior to all patients, and in the no POD24 group, subsequent OS was significantly superior to the POD24 group, although the clinical characteristics between the POD24 group and no POD24 group were not significantly different. Twenty-three patients (20.7%) showed primary refractory disease to first-line therapy, and the prognosis was poor. The International Prognostic Index score and POD24 were identified as independent predictors in multivariate analysis for OS in all patients, and only performance status was an independent prognostic factor for OS in the POD24 group in multivariate analysis. In conclusion, the clinical significance of assessing POD24 in PTCL and the poor prognosis in patients with early disease progression were demonstrated. |
| doi_str_mv | 10.1007/s12185-020-02987-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2440470624</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2440470624</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-c0dbc24ae9f4c145c08e580bcad3a6a44770a9ea7d1b24e92a7d2df6718c52e3</originalsourceid><addsrcrecordid>eNp9kE9PwyAYh4nRuDn9Ah5MEy9eqkBpoUdj5p9kiZddPBFG324stFRYNfv2snVq4sEDgYTn9_LjQeiS4FuCMb8LhBKRp5jiuErBU36ExkQUeZpxzo7RGJc0T3NO8AidhbDGmHDM-CkaZVSIgnIxRm_TD2V7tTGuTVyddN4tWxdMSGpnrfs07TIB5e02qUwAFWBPeAhhFzBt0oE33Qq8ssk81WBtYrdNt3KNOkcntbIBLg77BM0fp_OH53T2-vTycD9LdVaWm1TjaqEpU1DWTBOWaywgF3ihVZWpQjHGOVYlKF6RBWVQ0niiVV1wInROIZugm2FsLPbeQ9jIxoRdEdWC64OkjMU_44KyiF7_Qdeu920sFylOShp1ZZGiA6W9C8FDLTtvGuW3kmC58y4H7zJ6l3vvksfQ1WF0v2ig-ol8i45ANgAhXrVL8L9v_zP2C5OTjwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2471929253</pqid></control><display><type>article</type><title>Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Suzuki, Yasuhiro ; Yano, Takahiro ; Suehiro, Youko ; Iwasaki, Hiromi ; Hidaka, Michihiro ; Otsuka, Maki ; Sunami, Kazutaka ; Ikeda, Hirokazu ; Sawamura, Morio ; Ito, Takuo ; Iida, Hiroatsu ; Nagai, Hirokazu</creator><creatorcontrib>Suzuki, Yasuhiro ; Yano, Takahiro ; Suehiro, Youko ; Iwasaki, Hiromi ; Hidaka, Michihiro ; Otsuka, Maki ; Sunami, Kazutaka ; Ikeda, Hirokazu ; Sawamura, Morio ; Ito, Takuo ; Iida, Hiroatsu ; Nagai, Hirokazu</creatorcontrib><description>Recently, progression of disease within 24 months (POD24) has been demonstrated as a strong prognostic indicator in various types of malignant lymphoma. Peripheral T-cell lymphoma (PTCL) has an aggressive course and poor clinical outcomes. In this multicenter retrospective study, 111 consecutively registered patients with newly diagnosed PTCL were analyzed. Of these patients, 72 (64.9%) experienced POD24 (POD24 group), and the other 39 patients (35.1%) were analyzed as the no POD24 group. In the POD24 group, overall survival (OS) was significantly inferior to all patients, and in the no POD24 group, subsequent OS was significantly superior to the POD24 group, although the clinical characteristics between the POD24 group and no POD24 group were not significantly different. Twenty-three patients (20.7%) showed primary refractory disease to first-line therapy, and the prognosis was poor. The International Prognostic Index score and POD24 were identified as independent predictors in multivariate analysis for OS in all patients, and only performance status was an independent prognostic factor for OS in the POD24 group in multivariate analysis. In conclusion, the clinical significance of assessing POD24 in PTCL and the poor prognosis in patients with early disease progression were demonstrated.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-020-02987-7</identifier><identifier>PMID: 32886278</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Disease Progression ; Female ; Hematology ; Humans ; Lymphocytes T ; Lymphoma ; Lymphoma, T-Cell, Peripheral - therapy ; Male ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Multicenter Studies as Topic ; Multivariate analysis ; Oncology ; Original Article ; Prognosis ; Research Design ; Retrospective Studies ; Stem Cell Transplantation ; T-cell lymphoma ; Time Factors ; Young Adult</subject><ispartof>International journal of hematology, 2020-12, Vol.112 (6), p.817-824</ispartof><rights>Japanese Society of Hematology 2020</rights><rights>Japanese Society of Hematology 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-c0dbc24ae9f4c145c08e580bcad3a6a44770a9ea7d1b24e92a7d2df6718c52e3</citedby><cites>FETCH-LOGICAL-c399t-c0dbc24ae9f4c145c08e580bcad3a6a44770a9ea7d1b24e92a7d2df6718c52e3</cites><orcidid>0000-0002-1108-4540</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-020-02987-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-020-02987-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32886278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suzuki, Yasuhiro</creatorcontrib><creatorcontrib>Yano, Takahiro</creatorcontrib><creatorcontrib>Suehiro, Youko</creatorcontrib><creatorcontrib>Iwasaki, Hiromi</creatorcontrib><creatorcontrib>Hidaka, Michihiro</creatorcontrib><creatorcontrib>Otsuka, Maki</creatorcontrib><creatorcontrib>Sunami, Kazutaka</creatorcontrib><creatorcontrib>Ikeda, Hirokazu</creatorcontrib><creatorcontrib>Sawamura, Morio</creatorcontrib><creatorcontrib>Ito, Takuo</creatorcontrib><creatorcontrib>Iida, Hiroatsu</creatorcontrib><creatorcontrib>Nagai, Hirokazu</creatorcontrib><title>Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Recently, progression of disease within 24 months (POD24) has been demonstrated as a strong prognostic indicator in various types of malignant lymphoma. Peripheral T-cell lymphoma (PTCL) has an aggressive course and poor clinical outcomes. In this multicenter retrospective study, 111 consecutively registered patients with newly diagnosed PTCL were analyzed. Of these patients, 72 (64.9%) experienced POD24 (POD24 group), and the other 39 patients (35.1%) were analyzed as the no POD24 group. In the POD24 group, overall survival (OS) was significantly inferior to all patients, and in the no POD24 group, subsequent OS was significantly superior to the POD24 group, although the clinical characteristics between the POD24 group and no POD24 group were not significantly different. Twenty-three patients (20.7%) showed primary refractory disease to first-line therapy, and the prognosis was poor. The International Prognostic Index score and POD24 were identified as independent predictors in multivariate analysis for OS in all patients, and only performance status was an independent prognostic factor for OS in the POD24 group in multivariate analysis. In conclusion, the clinical significance of assessing POD24 in PTCL and the poor prognosis in patients with early disease progression were demonstrated.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Lymphoma, T-Cell, Peripheral - therapy</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multicenter Studies as Topic</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prognosis</subject><subject>Research Design</subject><subject>Retrospective Studies</subject><subject>Stem Cell Transplantation</subject><subject>T-cell lymphoma</subject><subject>Time Factors</subject><subject>Young Adult</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE9PwyAYh4nRuDn9Ah5MEy9eqkBpoUdj5p9kiZddPBFG324stFRYNfv2snVq4sEDgYTn9_LjQeiS4FuCMb8LhBKRp5jiuErBU36ExkQUeZpxzo7RGJc0T3NO8AidhbDGmHDM-CkaZVSIgnIxRm_TD2V7tTGuTVyddN4tWxdMSGpnrfs07TIB5e02qUwAFWBPeAhhFzBt0oE33Qq8ssk81WBtYrdNt3KNOkcntbIBLg77BM0fp_OH53T2-vTycD9LdVaWm1TjaqEpU1DWTBOWaywgF3ihVZWpQjHGOVYlKF6RBWVQ0niiVV1wInROIZugm2FsLPbeQ9jIxoRdEdWC64OkjMU_44KyiF7_Qdeu920sFylOShp1ZZGiA6W9C8FDLTtvGuW3kmC58y4H7zJ6l3vvksfQ1WF0v2ig-ol8i45ANgAhXrVL8L9v_zP2C5OTjwg</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Suzuki, Yasuhiro</creator><creator>Yano, Takahiro</creator><creator>Suehiro, Youko</creator><creator>Iwasaki, Hiromi</creator><creator>Hidaka, Michihiro</creator><creator>Otsuka, Maki</creator><creator>Sunami, Kazutaka</creator><creator>Ikeda, Hirokazu</creator><creator>Sawamura, Morio</creator><creator>Ito, Takuo</creator><creator>Iida, Hiroatsu</creator><creator>Nagai, Hirokazu</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1108-4540</orcidid></search><sort><creationdate>20201201</creationdate><title>Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma</title><author>Suzuki, Yasuhiro ; Yano, Takahiro ; Suehiro, Youko ; Iwasaki, Hiromi ; Hidaka, Michihiro ; Otsuka, Maki ; Sunami, Kazutaka ; Ikeda, Hirokazu ; Sawamura, Morio ; Ito, Takuo ; Iida, Hiroatsu ; Nagai, Hirokazu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-c0dbc24ae9f4c145c08e580bcad3a6a44770a9ea7d1b24e92a7d2df6718c52e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Lymphoma, T-Cell, Peripheral - therapy</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multicenter Studies as Topic</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prognosis</topic><topic>Research Design</topic><topic>Retrospective Studies</topic><topic>Stem Cell Transplantation</topic><topic>T-cell lymphoma</topic><topic>Time Factors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Yasuhiro</creatorcontrib><creatorcontrib>Yano, Takahiro</creatorcontrib><creatorcontrib>Suehiro, Youko</creatorcontrib><creatorcontrib>Iwasaki, Hiromi</creatorcontrib><creatorcontrib>Hidaka, Michihiro</creatorcontrib><creatorcontrib>Otsuka, Maki</creatorcontrib><creatorcontrib>Sunami, Kazutaka</creatorcontrib><creatorcontrib>Ikeda, Hirokazu</creatorcontrib><creatorcontrib>Sawamura, Morio</creatorcontrib><creatorcontrib>Ito, Takuo</creatorcontrib><creatorcontrib>Iida, Hiroatsu</creatorcontrib><creatorcontrib>Nagai, Hirokazu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Yasuhiro</au><au>Yano, Takahiro</au><au>Suehiro, Youko</au><au>Iwasaki, Hiromi</au><au>Hidaka, Michihiro</au><au>Otsuka, Maki</au><au>Sunami, Kazutaka</au><au>Ikeda, Hirokazu</au><au>Sawamura, Morio</au><au>Ito, Takuo</au><au>Iida, Hiroatsu</au><au>Nagai, Hirokazu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>112</volume><issue>6</issue><spage>817</spage><epage>824</epage><pages>817-824</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Recently, progression of disease within 24 months (POD24) has been demonstrated as a strong prognostic indicator in various types of malignant lymphoma. Peripheral T-cell lymphoma (PTCL) has an aggressive course and poor clinical outcomes. In this multicenter retrospective study, 111 consecutively registered patients with newly diagnosed PTCL were analyzed. Of these patients, 72 (64.9%) experienced POD24 (POD24 group), and the other 39 patients (35.1%) were analyzed as the no POD24 group. In the POD24 group, overall survival (OS) was significantly inferior to all patients, and in the no POD24 group, subsequent OS was significantly superior to the POD24 group, although the clinical characteristics between the POD24 group and no POD24 group were not significantly different. Twenty-three patients (20.7%) showed primary refractory disease to first-line therapy, and the prognosis was poor. The International Prognostic Index score and POD24 were identified as independent predictors in multivariate analysis for OS in all patients, and only performance status was an independent prognostic factor for OS in the POD24 group in multivariate analysis. In conclusion, the clinical significance of assessing POD24 in PTCL and the poor prognosis in patients with early disease progression were demonstrated.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>32886278</pmid><doi>10.1007/s12185-020-02987-7</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1108-4540</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2020-12, Vol.112 (6), p.817-824 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2440470624 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Disease Progression Female Hematology Humans Lymphocytes T Lymphoma Lymphoma, T-Cell, Peripheral - therapy Male Medical prognosis Medicine Medicine & Public Health Middle Aged Multicenter Studies as Topic Multivariate analysis Oncology Original Article Prognosis Research Design Retrospective Studies Stem Cell Transplantation T-cell lymphoma Time Factors Young Adult |
| title | Evaluation of prognosis following early disease progression in peripheral T-cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T12%3A08%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20prognosis%20following%20early%20disease%20progression%20in%20peripheral%20T-cell%20lymphoma&rft.jtitle=International%20journal%20of%20hematology&rft.au=Suzuki,%20Yasuhiro&rft.date=2020-12-01&rft.volume=112&rft.issue=6&rft.spage=817&rft.epage=824&rft.pages=817-824&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-020-02987-7&rft_dat=%3Cproquest_cross%3E2440470624%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2471929253&rft_id=info:pmid/32886278&rfr_iscdi=true |